Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma

Published:2020-01 Issue:1 Volume:20 Page:8-17.e16
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Chari Ajai^ORCID,Romanus Dorothy,Palumbo Antonio,Blazer Marlo,Farrelly Eileen,Raju Aditya^ORCID,Huang Hui,Richardson Paul

Funder

Oncopeptides

Celgene

Takeda

Bristol-Myers Squibb

Karyopharm

Amgen

Janssen

Pharmacycics

Novartis

Array BioPharma

The Binding Site

Seattle Genetics

Adaptive Biotechnology

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference26 articles.

1. Implications of heterogeneity in multiple myeloma;del Mel;BioMed Res Int,2014

2. Daratumumab, bortezomib, and dexamethasone for multiple myeloma;Palumbo;N Engl J Med,2016

3. Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: a personalized approach;Larocca;J Clin Oncol,2016

4. Management of older adults with multiple myeloma;Palumbo;Blood Rev,2013

5. Enrollment of older adults on oncology trials: an FDA perspective;Singh;J Geriatr Oncol,2017

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond BCMA: newer immune targets in myeloma;Blood Advances;2024-08-16

2. A roadmap towards improving outcomes in multiple myeloma;Blood Cancer Journal;2024-08-12

3. Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study;Clinical Lymphoma Myeloma and Leukemia;2024-06

4. The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR);BMC Medical Research Methodology;2024-05-02

5. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study;European Journal of Haematology;2024-04-23